Skip to main content
Caplight Logo









ONK Therapeutics

ONK Therapeutics

Private
IrelandHealthcare & Life Scienceshttps://www.onktherapeutics.com/

Last Round

Series A

Jan 6, 2022

Total Funding Raised

$33.45M

Company Overview

ONK Therapeutics is a biotechnology company that develops next-generation, off-the-shelf, optimally engineered natural killer (NK) cell therapies for the treatment of hematological malignancies and solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

natural killer cell therapyNK cell therapyallogeneic cell therapyoff-the-shelf therapycell engineeringoncologyhematological malignanciessolid tumorsgenetically engineered cellsbiopharmaceuticalCAR-NKnext-gen immunotherapyclinical-stage biotechdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ONK Therapeutics Comparables

Compare ONK Therapeutics with similar companies based on industry and business-model similarity.

ONK Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CytoImmune Therapeutics
89%
NK:IO
84%
Glycostem Therapeutics
83%

ONK Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 6, 2022
GrantJun 8, 2021
VC RoundOct 19, 2020
SeedMay 1, 2020
GrantDec 10, 2018

ONK Therapeutics Investors

Notable investors and investment history

ONK Therapeutics investors
InvestorRounds
Cormorant Asset ManagementSeries A
Acorn BioventuresSeries A, VC Round
Enterprise IrelandGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Monthly visitors increased 39% MoM.

  • Nov 9, 2025

    Monthly visitors increased 46% MoM.

ONK Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ONK Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ONK Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersIreland
Employee Range15
Year Founded2015
Last FundingJan 6, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?